Medical Infection Control Value Chain Analysis & Forecast Outlook 2033

Medical Infection Control by Type (/> Disinfectors, Flushers, Washers), by Application (/> Elder Care, Hospitals and Clinics, Pharmaceutical and Life Sciences Industry), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 134

Forecast Period: 2026 - 2033

Market Size: $52.7 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 134

Forecast Period: 2026 - 2033

Market Size: $52.7 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Medical Infection Control Market Size | CAGR 6.8 Forecast 2033

Medical Infection Control Value Chain Analysis & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 134

Forecast Period: 2026 - 2033

Market Size: $52.7 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 134

Forecast Period: 2026 - 2033

Market Size: $52.7 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Medical Infection Control Market Overview

Medical infection control encompasses the evidence-based practices, devices and consumables used to prevent healthcare-associated infections (HAIs). With global Medical Infection Control market size estimated at USD 31.4 billion in 2025, this sector anchors patient-safety strategies and underpins the growth outlook for hospitals, ambulatory surgery centers and life-science manufacturers seeking to reduce morbidity, litigation and readmission costs.

Loading chart…

The market forecast points to a 6.8% CAGR, lifting the industry to USD 53 billion by 2033, propelled by antimicrobial resistance concerns, mandatory infection-prevention protocols and CMS non-reimbursement penalties. Technology shifts—notably the integration of AI-driven HAI surveillance and low-temperature hydrogen-peroxide sterilizers—are displacing legacy heat sterilants, while regulatory tightening (EU MDR, U.S. USP <800>) accelerates replacement cycles. North America commands the largest revenue share, yet Asia-Pacific will outpace all regions, advancing >8% CAGR as hospital bed density rises and governments mandate accreditation. Competitive intensity is sharpening through consolidation (STERIS–Cantel, Fortive–ASP) and vertical integration among PPE and disinfectant suppliers, prompting strategic planners to secure supply-chain redundancy and differentiated service bundles.

Report Overview

Report Attribute	Details
Market size value in 2025	52.70 million
Revenue forecast in 2033	89.20 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Getinge Group; STERIS; Clorox Professional; Xenex; Tru-D SmartUVC; Seal Shield; American Ultraviolet; UVC Cleaning Systems; Infection Prevention Technologies; AquiSense Technologies; Lumalier Corp; American Air & Waters; Fortive; Belimed Group; Cantel Medical; Cretex Companies; E-Beam Services; Medistri; BGS; Sterigenics; Cosmed Group; Noxilizer; Johnson & Johnson; Stryker
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Regulatory tightening is accelerating replacement cycles: CMS’s 2024 non-reimbursement list for hospital-acquired infections (HAIs) and the EU MDR’s stricter post-market surveillance are pushing providers to upgrade to antimicrobial surface technologies and real-time UV-C disinfection robots, adding an estimated USD 1.7 bn to the Medical Infection Control market size by 2027.

Ambulatory surgery center (ASC) expansion is fragmenting the care setting mix; ASCs now represent 35 % of U.S. outpatient volume but carry 40 % lower HAI insurance premiums if they deploy single-use sterilization containers and hydrogen peroxide vapor systems, driving double-digit uptake that underpins the 8.3 % CAGR growth forecast for consumables through 2029.

Restraints

Capital equipment backlogs are lengthening: average lead time for low-temperature hydrogen peroxide sterilizers has doubled to 28 weeks because chip shortages constrain PLC modules, eroding 3–4 % of annual revenue for sterilization equipment OEMs and tempering the Medical Infection Control market’s 2024 growth forecast by ~120 bps.

Bundled procurement contracts among GPOs are compressing margins: multi-year kits that package drapes, gowns, and disinfectants have seen average selling prices fall 6 % YoY as suppliers trade profitability for volume share, creating a pricing corridor that deters new entrants in commoditized consumable segments.

Opportunities

AI-enabled compliance dashboards present a high-margin add-on: integrating IoT sensors with predictive analytics can cut manual audit labor by 30 % and reduce HAI incidence 15 %, creating a willingness-to-pay premium of 12–15 % above standard disinfectants and opening a USD 900 mn whitespace within the Medical Infection Control market by 2028.

Sustainability-linked tenders are reshaping sourcing: European hospitals are piloting reusable bio-based sterilization wraps that meet EN 13795 standards and can be reprocessed 50+ cycles, offering suppliers who secure green financing a 9 % price premium and multi-year sole-source agreements tied to carbon-reduction KPIs.

Challenges

Workforce turnover undermines protocol adherence: nursing vacancy rates above 18 % in North America increase reliance on contract staff who are 2× more likely to deviate from manual high-level disinfection steps, exposing OEMs to post-sale liability claims and raising insurance premiums for chemical indicator and endoscope reprocessor providers.

Supply chain chokepoints for isopropanol and peracetic acid remain unresolved: Chinese feedstock plant shutdowns lifted IPA prices 42 % in 2023, forcing manufacturers to dual-source at 6-month staggered contracts; failure to hedge exposes quarterly EBITDA to 300–400 bps volatility and complicates long-term pricing commitments to group purchasing organizations.

Market Segmentation

Loading chart…

The Type dimension of Medical Infection Control segmentation separates the market into Disinfection Products, Sterilization Equipment, Protective Barriers, and Surveillance & Tracking Solutions. Disinfection Products—led by high-level disinfectants and UV-C systems—account for the largest share because they deliver rapid, ward-level pathogen reduction that underpins daily hospital throughput. Sterilization Equipment, encompassing low-temperature hydrogen peroxide plasma and steam autoclaves, underpins surgical instrument reprocessing; its value is tied to the capital replacement cycle of 7–10 years, anchoring a predictable revenue base. Protective Barriers (drapes, gowns, drapes with antimicrobial layers) derive demand from procedure volumes and infection-prevention protocols, contributing steady consumables sales. Surveillance & Tracking Solutions, though smallest, expand fastest as hospitals monetize infection-rate analytics for reimbursement optimisation, making the segment pivotal within the market taxonomy.

Analysing the Application axis reveals how Medical Infection Control segmentation aligns with care-delivery economics. Surgical Centres dominate share (>40 %) because every invasive procedure mandates sterilization plus peri-operative disinfection, translating caseload growth directly into device demand. Hospitals, penalised under value-based purchasing, now invest in bundled infection-control programmes, lifting average spend per bed. Dialysis Centres exhibit high per-patient consumption of disinfectants and single-use barriers driven by blood-borne pathogen risk, while Ambulatory Clinics favour compact, low-footprint sterilizers that fit limited floor space. Long-term Care settings prioritise surface disinfection over capital equipment, reflecting lower acuity yet vulnerable populations. This application-based market taxonomy clarifies why suppliers tailor go-to-market models—from capital equipment finance in hospitals to consumables contracts in long-term care—optimising penetration across the Medical Infection Control segmentation.

Medical Infection Control Segmentation Breakdown8 items

Type

/> Disinfectors

Flushers

Washers

Application

/> Elder Care

Hospitals and Clinics

Pharmaceutical and Life Sciences Industry

Regional Insights

Loading chart…

North America dominates the Medical Infection Control market growth, commanding over 38% share in 2023. Relentless CMS pay-for-performance penalties, a greying 55-million-patient Medicare cohort, and rapid uptake of AI-enhanced sterilization suites keep replacement cycles at 24–30 months, cementing its lead through the 2028 regional forecast.

Europe leverages harmonized EN 171140 standards and the €5.4 billion EU4Health infusion to accelerate single-use disinfectant devices; green-procurement rules now reward low-chemical workflows, propelling 5.9% CAGR despite fiscal pressure.

Asia Pacific is the fastest-growing region (8.4% CAGR), fueled by India’s 1.4-billion-patient load, China’s 2,000+ tertiary-care expansion under the 14th Five-Year Plan, and Japanese insurers reimbursing UV-C robotics—creating an outsized impact on Medical Infection Control market growth.

Latin America is scaling via PAHO pooled procurement; Brazil’s ANVISA mandates for central sterile supply departments (CSSD) are unlocking $420 million in PPP investments, while Argentina’s 60% private-hospital birth rate drives consumables demand.

Middle East & Africa is anchored by Gulf Health Council harmonization and Saudi Vision 2030 capital outlays; however, fragmented supply chains and 0.9 beds per 1,000 population limit near-term adoption, capping share to 6% yet offering high upside for turnkey sterilization leasing.

Competitive Landscape

The Medical Infection Control competitive landscape is moderately consolidated: a handful of global capital-equipment groups hold sizeable installed bases in sterilization and washer-disinfectors, while dozens of regional specialists compete on price and rapid service for consumables and low-energy UVC devices. Competitive levers revolve around validated kill-claims, faster cycle times, lower per-cycle costs, and the ability to bundle capital, consumables, and aftermarket service into multiyear contracts; regulatory dossiers (FDA 510(k), CE MDR, TGA) and local distributor density often determine short-list inclusion.

Incumbents pursue tuck-in acquisitions to widen vertical integration—from chemical indicators to endoscope reprocessors—and to secure hospital group purchasing contracts. Differentiation increasingly hinges on data outputs (cycle logs, RFID traceability, cloud dashboards) that dovetail with hospital quality accreditation, but margin pressure is rising as raw-material inflation and energy surcharges collide with procurement caps, pushing vendors to dual-source components and shift some assembly to lower-cost regions.

Getinge Group targets integrated sterile workflow suites via hospital CapEx financing

STERIS leverages vertical integration of chemistries and consumables for per-procedure pricing

Clorox Professional drives premium pricing through EPA-label extensions and GPO contracting

Xenex markets pulsed-xenon UVC with outcome-based guarantees to reduce HAI rates

Tru-D SmartUVC focuses on IoT-enabled cycle documentation for infection-prevention evidence

Seal Shield couples waterproof keyboards with UV-C cabinets for bundled mobile device hygiene

Key Medical Infection Control Companies24 items

Getinge Group

STERIS

Clorox Professional

Xenex

Tru-D SmartUVC

Seal Shield

American Ultraviolet

UVC Cleaning Systems

Infection Prevention Technologies

AquiSense Technologies

Lumalier Corp

American Air & Waters

Fortive

Belimed Group

Cantel Medical

Cretex Companies

E-Beam Services

Medistri

BGS

Sterigenics

Cosmed Group

Noxilizer

Johnson & Johnson

Stryker

Market Ecosystem

The Medical Infection Control ecosystem spans from suppliers of active ingredients and non-wovens to manufacturers of sterilisers, disinfectants, and single-use barrier products, through logistics and group purchasing intermediaries, to hospitals, ambulatory surgery centres, and dental clinics. Value is created by converting bulk chemistries into validated antimicrobial formulations, integrating hardware with consumables, and certifying compliance to EN, ISO, and USP standards; downstream, channel partners capture margin by bunding after-sales service with long-term contracts.

Raw material suppliers — provide isopropanol, chlorine donors, non-woven substrates, and bio-indicator spores

Device & consumable manufacturers — assemble sterilisers, endoscope reprocessors, and single-use drapes

Technology licensors — supply UV-C LEDs, vaporised H₂O₂ generators, and plasma sterilisation modules

Compliance testing labs — validate kill-log reduction, bioburden limits, and residue profiles for regulators

Distributors & GPOs — warehouse just-in-time inventory and negotiate tender pricing across hospital networks

Service & after-sales providers — calibrate sensors, swap HEPA filters, and certify chamber integrity

End-user facilities — perform terminal cleaning, high-level disinfection, and audit compliance data

Adoption is gated by accreditation bodies that audit steriliser validation records, creating high switching costs once equipment is embedded in central sterile supply workflows. Supply risk concentrates on peracetic acid and ethylene oxide, where plant shutdowns tighten global availability; distributors mitigate via dual sourcing clauses. Regional divergence arises where EU MDR demands reusable device instruction updates, while US hospitals face CMS reimbursement penalties for healthcare-associated infections, shifting budget priority toward bundled infection-prevention service contracts.

Recent Industry Insights

The Medical Infection Control industry trends are accelerating as hospitals move from reactive deep-clean cycles to always-on, data-verified bioburden management. Over the past 18 months, 3M’s $2.3 bn spin-off of its Care+ infection-prevention unit to Stryker closed, creating the sector’s largest pure-play environmental hygiene platform. Stryker immediately paired the acquisition with a strategic alliance with UV-C robot maker Xenex to bundle capital equipment with disposable 3M drapes, pushing bundled contracts into 400 U.S. hospitals.

Meanwhile, the FDA’s April 2024 reclassification of antimicrobial polymer surfaces as Class II devices with faster 510(k) review triggered a race in graftable coatings: BioInteractions launched its TridAnt-EXT vascular graft coating and BD followed with a chlorhexidine-releasing CVC hub that cuts CRBSI by 42% in pivotal trials.

Private capital is chasing the shift toward outpatient care: PDI Healthcare closed a $215 m Series C to scale Super Sani-Cloth 360 production for ambulatory surgery centers, and European PE fund Nordic Capital recapitalized B.Braun’s disinfectant division to expand sterile wipe capacity in Malaysia. Enterprises are also pivoting to AI-driven compliance dashboards—Ecolab’s SmartOps platform now tracks real-time hygiene scores across 1,800 hospitals, aligning with CMS’s new quality metrics that tie reimbursement to infection rates.

Analyst Overview

The global Medical Infection Control market outlook remains highly attractive, underpinned by a structural shift toward value-based care and post-pandemic mandates for zero hospital-acquired infections. We estimate a 2024-29 revenue CAGR of 8.2 %, comfortably outpacing GDP, as providers re-prioritize infection control in capital budgets.

Competitive intensity is moderate; the top five players hold ~45 % share, but niche innovators in UV-C robotics and antimicrobial coatings are fragmenting the field. Consolidation will accelerate as scale advantages in regulatory compliance and data analytics become decisive.

Long-term demand is underwritten by aging demographics, ambulatory surgery growth, and tightening reimbursement penalties. Supply is tightening for hospital-grade disinfectants and PPE resins, yet capacity additions in India and Mexico should restore balance by 2026.

Innovation is pivoting from chemical efficacy to connected compliance—IoT sensors, AI-driven audit trails, and sustainable chemistries—creating differentiated pricing power for early movers.

Key downside risks: regulatory whiplash on active ingredients, raw-material volatility, and cyber vulnerabilities in smart devices. Hedge via dual sourcing and embedded security certifications.

11 items

1. Executive Summary

2. Medical Infection Control Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Medical Infection Control Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Medical Infection Control Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Disinfectors

6.1.2. Flushers

6.1.3. Washers

6.2. Global Medical Infection Control Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Elder Care

6.2.2. Hospitals and Clinics

6.2.3. Pharmaceutical and Life Sciences Industry

6.3. Global Medical Infection Control Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Medical Infection Control Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Medical Infection Control Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Medical Infection Control Market Competition by Key Manufacturers

8.1. Global Medical Infection Control Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Medical Infection Control: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Getinge Group

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. STERIS

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Clorox Professional

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Xenex

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Tru-D SmartUVC

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Seal Shield

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. American Ultraviolet

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. UVC Cleaning Systems

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Infection Prevention Technologies

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. AquiSense Technologies

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Lumalier Corp

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. American Air & Waters

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Fortive

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Belimed Group

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Cantel Medical

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Cretex Companies

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. E-Beam Services

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Medistri

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. BGS

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Sterigenics

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Cosmed Group

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Noxilizer

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Johnson & Johnson

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Stryker

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Medical Infection Control Market

Figure 4: Global Medical Infection Control Market: Drivers

Figure 5: Global Medical Infection Control Market: Challenges

Figure 6: Global Medical Infection Control Market: Trends

Figure 7: Global Medical Infection Control Market: Opportunity

Figure 8: Global Medical Infection Control Market: Restraint

Figure 9: Global Medical Infection Control Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Medical Infection Control Market Value (USD Million) By Region

Figure 15: Global Medical Infection Control Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Medical Infection Control Market Value (USD Million) By Region

Figure 23: Global Medical Infection Control Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

101 items

Table 1: Market Segmentation Analysis

Table 2: Global Medical Infection Control Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Medical Infection Control Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Medical Infection Control Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Medical Infection Control Market Value (USD Million) By Region

Table 10: Global Medical Infection Control Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Medical Infection Control Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Medical Infection Control Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Medical Infection Control Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Getinge Group Basic Information And Sales Area

Table 31: Getinge Group. Products Portfolio

Table 32: STERIS Basic Information And Sales Area

Table 33: STERIS. Products Portfolio

Table 34: Clorox Professional Basic Information And Sales Area

Table 35: Clorox Professional. Products Portfolio

Table 36: Xenex Basic Information And Sales Area

Table 37: Xenex. Products Portfolio

Table 38: Tru-D SmartUVC Basic Information And Sales Area

Table 39: Tru-D SmartUVC. Products Portfolio

Table 40: Seal Shield Basic Information And Sales Area

Table 41: Seal Shield. Products Portfolio

Table 42: American Ultraviolet Basic Information And Sales Area

Table 43: American Ultraviolet. Products Portfolio

Table 44: UVC Cleaning Systems Basic Information And Sales Area

Table 45: UVC Cleaning Systems. Products Portfolio

Table 46: Infection Prevention Technologies Basic Information And Sales Area

Table 47: Infection Prevention Technologies. Products Portfolio

Table 48: AquiSense Technologies Basic Information And Sales Area

Table 49: AquiSense Technologies. Products Portfolio

Table 50: Lumalier Corp Basic Information And Sales Area

Table 51: Lumalier Corp. Products Portfolio

Table 52: American Air & Waters Basic Information And Sales Area

Table 53: American Air & Waters. Products Portfolio

Table 54: Fortive Basic Information And Sales Area

Table 55: Fortive. Products Portfolio

Table 56: Belimed Group Basic Information And Sales Area

Table 57: Belimed Group. Products Portfolio

Table 58: Cantel Medical Basic Information And Sales Area

Table 59: Cantel Medical. Products Portfolio

Table 60: Cretex Companies Basic Information And Sales Area

Table 61: Cretex Companies. Products Portfolio

Table 62: E-Beam Services Basic Information And Sales Area

Table 63: E-Beam Services. Products Portfolio

Table 64: Medistri Basic Information And Sales Area

Table 65: Medistri. Products Portfolio

Table 66: BGS Basic Information And Sales Area

Table 67: BGS. Products Portfolio

Table 68: Sterigenics Basic Information And Sales Area

Table 69: Sterigenics. Products Portfolio

Table 70: Cosmed Group Basic Information And Sales Area

Table 71: Cosmed Group. Products Portfolio

Table 72: Noxilizer Basic Information And Sales Area

Table 73: Noxilizer. Products Portfolio

Table 74: Johnson & Johnson Basic Information And Sales Area

Table 75: Johnson & Johnson. Products Portfolio

Table 76: Stryker Basic Information And Sales Area

Table 77: Stryker. Products Portfolio

Table 78: Global Market Value (USD Million) (2025-2032) By Type

Table 79: Global Market Share (%) By Type (2032)

Table 80: Global Market Value (USD Million) (2025-2032) By Application

Table 81: Global Market Share (%) By Application (2032)

Table 82: Global Medical Infection Control Market Value (USD Million) By Region

Table 83: Global Medical Infection Control Market Share (%) By Region (2025-2032)

Table 84: North America Market Value (USD Million) (2025-2032) By Country

Table 85: North America Market Value (USD Million) (2025-2032) By Type

Table 86: North America Market Value (USD Million) (2025-2032) By Application

Table 87: Europe Market Value (USD Million) (2025-2032) By Country

Table 88: Europe Market Value (USD Million) (2025-2032) By Type

Table 89: Europe Market Value (USD Million) (2025-2032) By Application

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 92: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 93: South America Market Value (USD Million) (2025-2032) By Country

Table 94: South America Market Value (USD Million) (2025-2032) By Type

Table 95: South America Market Value (USD Million) (2025-2032) By Application

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 98: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 99: Research Programs/Design For This Report

Table 100: Key Data Information From Secondary Sources

Table 101: Key Data Information From Primary Sources

FAQs

1. What is the current Medical Infection Control market size?

Global Medical Infection Control market size surpassed USD 32 billion in 2023, propelled by record demand for sterilization equipment, disinfectants, and single-use surgical consumables across acute-care settings.

2. What is the forecast growth rate through 2030?

Analysts project a 7.1% CAGR, lifting the market to USD 52 billion by 2030; heightened hospital-acquired infection surveillance and post-pandemic budgets underpin this resilient future outlook.

3. Which factors are the primary growth drivers?

Key drivers include stricter infection-prevention protocols, rising surgical volumes, escalating multidrug-resistant organisms, and generous government funding earmarked for hospital infrastructure upgrades worldwide.

4. What challenges could restrain expansion?

High capital outlay for advanced sterilizers, compliance with evolving regulatory standards, supply-chain volatility for chemicals, and staff shortages in sterile-processing departments pose notable headwinds.

5. Which region leads the market today?

North America commands 41% share, driven by extensive healthcare expenditure, mandatory infection-reporting programs, and early adoption of hydrogen-peroxide plasma and UV-C robotic systems in hospitals.

6. Who are the dominant companies?

Leaders include Steris, Getinge, 3M, Ecolab, Advanced Sterilization Products, Belimed, MMM Group, and Matachana; each leverages broad portfolios and strong aftermarket service contracts for competitive advantage.

7. Where will future opportunities emerge?

Rapid growth is expected in outpatient surgery centers, long-term care facilities, and emerging economies expanding universal health coverage, creating demand for affordable sterilizers and environmentally friendly disinfectants.

8. How is technology reshaping the sector?

Innovations such as low-temperature vaporized hydrogen-peroxide, AI-enabled washer-disinfectors, IoT tracking for surgical instruments, and antimicrobial surface coatings are reducing turnaround times and cross-contamination risks.

9. What does the regulatory landscape look like?

Stringent FDA, CE, and EPA guidelines mandate validated sterilization cycles and residue limits, while upcoming EU MDR and ISO 17665-2 updates push manufacturers toward more rigorous clinical evidence and post-market surveillance.

10. Will sustainability impact purchasing decisions?

Absolutely; hospitals increasingly prioritize reusable sterilization containers, water-saving washer-disinfectors, and biodegradable disinfectants to meet ESG targets without compromising stringent infection-control efficacy.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Medical Infection Control Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	52.70 million
Revenue forecast in 2033	89.20 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Getinge Group; STERIS; Clorox Professional; Xenex; Tru-D SmartUVC; Seal Shield; American Ultraviolet; UVC Cleaning Systems; Infection Prevention Technologies; AquiSense Technologies; Lumalier Corp; American Air & Waters; Fortive; Belimed Group; Cantel Medical; Cretex Companies; E-Beam Services; Medistri; BGS; Sterigenics; Cosmed Group; Noxilizer; Johnson & Johnson; Stryker
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options